Physician profile
Andrew Lin
NPI 1457694598
$18,762.80
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.71 · 2021: $1,430 · 2022: $16K · 2023: $539 · 2024: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $9,034.66 | 2021-2024 | Olumiant |
| Abbvie INC. | $6,479.05 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $707.31 | 2022-2024 | Sotyktu |
| Amgen INC. | $460.93 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $276.16 | 2021-2022 | |
| Pfizer INC. | $229.34 | 2022-2023 | |
| Ucb, INC. | $229.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $186.56 | 2021-2022 | |
| Leo Pharma INC. | $140.08 | 2021-2022 | |
| Incyte Corporation | $131.06 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $122.20 | 2021 | |
| Sun Pharmaceutical Industries INC. | $121.05 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $108.67 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $107.02 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $94.88 | 2021-2023 | |
| Genzyme Corporation | $77.00 | 2022 | |
| Janssen Biotech, INC. | $47.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.72 | 2022 | |
| Almirall LLC | $29.01 | 2022 | |
| Journey Medical Corporation | $26.89 | 2022 | |
| Mayne Pharma Commercial LLC | $21.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.